NCT06774625: An ongoing trial by Latigo Biotherapeutics
This trial is ongoing. It must report results 7 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06774625 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 19, 2024 |
| Completion date | Aug. 8, 2025 |
| Required reporting date | Aug. 8, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |